Osborne CK - Search Results

1

Pure antiestrogens. The most important advance in the endocrine therapy of breast cancer since 1896.

Nicholson RI, Gee JM, Bryant S, Francis AB, McClelland RA, Knowlden J, Wakeling AE, Osborne CK. Nicholson RI, et al. Among authors: osborne ck. Ann N Y Acad Sci. 1996 Apr 30;784:325-35. doi: 10.1111/j.1749-6632.1996.tb16247.x. Ann N Y Acad Sci. 1996. PMID: 8651581 Review. No abstract available.

2

Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer.

Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, McCue BL, Wakeling AE, McClelland RA, Manning DL, Nicholson RI. Osborne CK, et al. J Natl Cancer Inst. 1995 May 17;87(10):746-50. doi: 10.1093/jnci/87.10.746. J Natl Cancer Inst. 1995. PMID: 7563152

3

ICI 182,780 (Faslodex): development of a novel, "pure" antiestrogen.

Howell A, Osborne CK, Morris C, Wakeling AE. Howell A, et al. Among authors: osborne ck. Cancer. 2000 Aug 15;89(4):817-25. doi: 10.1002/1097-0142(20000815)89:4<817::aid-cncr14>3.0.co;2-6. Cancer. 2000. PMID: 10951345

4

Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Osborne CK, Wakeling A, Nicholson RI. Osborne CK, et al. Br J Cancer. 2004 Mar;90 Suppl 1(Suppl 1):S2-6. doi: 10.1038/sj.bjc.6601629. Br J Cancer. 2004. PMID: 15094757 Free PMC article. Review.

5

Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.

Massarweh S, Osborne CK, Jiang S, Wakeling AE, Rimawi M, Mohsin SK, Hilsenbeck S, Schiff R. Massarweh S, et al. Among authors: osborne ck. Cancer Res. 2006 Aug 15;66(16):8266-73. doi: 10.1158/0008-5472.CAN-05-4045. Cancer Res. 2006. PMID: 16912207

6

Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.

Shou J, Massarweh S, Osborne CK, Wakeling AE, Ali S, Weiss H, Schiff R. Shou J, et al. Among authors: osborne ck. J Natl Cancer Inst. 2004 Jun 16;96(12):926-35. doi: 10.1093/jnci/djh166. J Natl Cancer Inst. 2004. PMID: 15199112

7

The importance of tamoxifen metabolism in tamoxifen-stimulated breast tumor growth.

Osborne CK, Jarman M, McCague R, Coronado EB, Hilsenbeck SG, Wakeling AE. Osborne CK, et al. Cancer Chemother Pharmacol. 1994;34(2):89-95. doi: 10.1007/BF00685924. Cancer Chemother Pharmacol. 1994. PMID: 8194171

8

Proceedings of the First International Conference on Recent Advances and Future Directions in Endocrine Therapy for Breast Cancer: summary consensus statement.

Buzdar AU, Come SE, Brodie A, Ellis M, Goss PE, Ingle JN, Johnston SR, Lee AV, Osborne CK, Vogel VG, Hart CS. Buzdar AU, et al. Among authors: osborne ck. Clin Cancer Res. 2001 Dec;7(12 Suppl):4335s-4337s; discussion 4411s-4412s. Clin Cancer Res. 2001. PMID: 11916221 Review. No abstract available.

9

Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

Lu C, Speers C, Zhang Y, Xu X, Hill J, Steinbis E, Celestino J, Shen Q, Kim H, Hilsenbeck S, Mohsin SK, Wakeling A, Osborne CK, Brown PH. Lu C, et al. Among authors: osborne ck. J Natl Cancer Inst. 2003 Dec 17;95(24):1825-33. doi: 10.1093/jnci/djg117. J Natl Cancer Inst. 2003. PMID: 14679152

10

Mechanisms of endocrine resistance in breast cancer.

Osborne CK, Schiff R. Osborne CK, et al. Annu Rev Med. 2011;62:233-47. doi: 10.1146/annurev-med-070909-182917. Annu Rev Med. 2011. PMID: 20887199 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

372 results

Search Page